检索结果-南通市图书馆

Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes

Genes & Diseases 2023年第4期10卷 1641-1656页

作者： Kexin Li Xun Sun Hudie Li Hailan Ma Meng Zhou Kazumasa Minami Keisuke Tamari Kazuhiko Ogawa Pankita HPandya MReza Saadatzadeh melissa akacena Karen EPollok Bai-Yan Li Hiroki Yokota Department of Pharmacology School of PharmacyHarbin Medical UniversityHarbinHeilongjiang 150081China Department of Biomedical Engineering Indiana University Purdue University IndianapolisIndianapolisIN 46202USA Department of Radiation Oncology Osaka University Graduate School of MedicineSuitaOsaka 565-0871Japan Simon Comprehensive Cancer Center Indiana University School of MedicineIndianapolisIN 46202USA Department of Pediatrics Indiana University School of MedicineIndianapolisIN 46202USA Department of Orthopaedic Surgery Indiana University School of MedicineIndianapolisIN 46202USA Indiana Center for Musculoskeletal Health Indiana University School of MedicineIndianapolisIN 46202USA

Cancer cells tend to develop resistance to chemotherapy and enhance aggressive-ness.A counterintuitive approach is to tame aggressiveness by an agent that acts opposite to chemotherapeutic *** on this strategy,induced tumor-suppressing cells(iTSCs)have been generated from tumor cells and mesenchymal stem ***,we examined the possi-bility of generating iTSCs from lymphocytes by activating PKA signaling for suppressing the pro-gression of osteosarcoma(OS).While lymphocyte-derived CM did not present anti-tumor capabilities,the activation of PKA converted them into *** PKA conversely gener-ated tumor-promotive *** a mouse model,PKA-activated CM suppressed tumorinduced bone *** analysis revealed that moesin(MSN)and calreticulin(Calr),which are highly expressed intracellular proteins in many cancers,were enriched in PKA-activated CM,and they acted as extracellular tumor suppressors through CD44,CD47,and *** study presented a unique option for cancer treatment by generating iTSCs that secret tumor-suppressive proteins such as MSN and *** envision that identifying these tu-mor suppressors and predicting their binding partners such as CD44,which is an FDA-approved oncogenic target to be inhibited,may contribute to developing targeted protein therapy.

关键词： Calreticulin Lymphocytes Moesin Osteosarcoma PKA Proteome

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：